Hsp90 inhibitors with modified toxicity

US8551964B2 · kind B2 · utility

Assignee

• The Regents of the University of Colorado · US

Inventors

• David Ross · Cary, US
• David Siegel · Denver, US
• Wenchang Guo · Elk Grove, US
• Christopher J. Moody · Stevenage, GB
• Christopher S. P. McErlean · Calle de la Era, AU

Key dates

• Filing date: Aug 22, 2008
• Grant date: Oct 8, 2013
• Expiry date: May 31, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D225/06
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention provides 19-substituted geldanamycin derivatives, pharmaceutically acceptable salts thereof and prodrugs thereof that are potent Hsp90 binding agents useful for the treatment of, and/or the amelioration of symptoms of, cancer and other proliferative tissue disorders.